Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial
Carrie L. Kitko(Vanderbilt University Medical Center), John E. Levine(Icahn School of Medicine at Mount Sinai), Attaphol Pawarode(University of Michigan), James L.M. Ferrara(Tisch Hospital), Charles F. Schuler(University of Michigan), James A. Connelly(Michigan Center for Translational Pathology), Sung Won Choi(University of Michigan), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Pavan Reddy(Wichita State University), Gregory A. Yanik(University of Michigan), Thomas Braun(University of Michigan), Sandra Hoffmann(Economic Research Service), Steven C. Goldstein(University of Michigan), John Magenau(University of Michigan)
Cited by 35
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Annual Cost of Illness and Quality-Adjusted Life Year Losses in the United States Due to 14 Foodborne Pathogens
|Journal of Food Protection|2012|609
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577